<DOC>
	<DOCNO>NCT00004642</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate safety , tolerance , potential efficacy 3 dos human anti-cytomegalovirus ( CMV ) monoclonal antibody SDZ MSL-109 ( MOAB MSL-109 ) treatment newborns congenital CMV infection central nervous system disease . II . Determine relationship plasma concentration MOAB MSL-109 therapeutic outcome . III . Determine whether MOAB MSL-109 influence antibody response clearance virus urine .</brief_summary>
	<brief_title>Phase I/II Study Human Anti-Cytomegalovirus ( CMV ) Monoclonal Antibody MSL-109 Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients treat human anti-cytomegalovirus monoclonal antibody MSL-109 , administer intravenously every week total 3 dos . Groups 6 patient treat 3 MSL-109 dos ; intrapatient escalation . No concurrent therapy antibiotic systemic infection , parenteral antifungal agent , biological response modifier , antiviral agent allow . Patients follow every 2 week 6 week , every 4 week 12 week , annually 5 year .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Symptomatic congenital cytomegalovirus ( CMV ) infection confirm urine culture No CMV acquire natally postnatally Normal eye exam skull xray , computerized tomography , magnetic resonance image No evidence central nervous system CMV , e.g . : Microcephaly , hydrocephaly , hydranencephaly Intracranial calcification Chorioretinitis Normal cerebrospinal fluid Preterm : WBC great 30 Protein less 120 mg/dL Term : WBC great 25 Protein less 80 mg/dL Prior/Concurrent Therapy At least 2 week since investigational drug No prior concurrent antiviral agent Patient Characteristics Life expectancy : No imminent demise Renal : Creatinine great 1.5 mg/dL Other : Birth weight least 1200 g No congenital toxoplasmosis , congenital rubella , syphilis No active systemic infection , i.e . : Bacterial NonCMV viral , include HIV Protozoal Fungal No severe concurrent clinical condition , e.g . : NonCMV congenital disease Genetic abnormality Moderate severe hyaline membrane disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>29 Days</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>congenital cytomegalovirus infection</keyword>
	<keyword>cytomegalovirus infection</keyword>
	<keyword>herpesvirus infection</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>neonatal disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>viral infection</keyword>
</DOC>